“We found that the SAPS is associated with higher intrarenal pressure and flow rate when compared to automated pumps," said Lucas B. Vergamini, MD. A study evaluating intrarenal pressure and flow rate ...

In this video, 4 experts discuss the highlights and take-home messages from the 2024 American Urological Association Annual Meeting. Nielsen is the chair of urology and the John Sloan Rhodes and John ...

"There's definitely more work to do to confirm these results on a multi-institutional aspect," says Ryan L. Steinberg, MD. In this video, Ryan L. Steinberg, MD, discusses next steps following the ...

“All this is very detailed immunology, I get that, but it sets the stage for what I consider the next evolution of immunotherapy,” says Patrick Soon-Shiong, MD. In April 2024, the FDA approved N-803 ...

“What we need is continued work on integrating surgery and systemic therapy,” says Patrick Kenney, MD. In this interview, David Braun, MD, PhD, and Patrick Kenney, MD, describe their practices and ...

The phase 2/3 AlphaBreak trial is evaluating the safety and efficacy of FPI-2265 in patients with mCRPC who have been previously treated with 177Lu-PSMA radiotherapy. "Despite recent advances in the ...

“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.

“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab ...

Hiten D. Patel, MD, highlights the background and trial design for the study, “A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT ...

Findings presented at the 2024 AUA Annual Meeting showed that, among 136 cases of patients with UTUC treated with UGN-101, the 3-year rate of RFS was 68%. The outcomes did not significantly differ ...

The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025. The FDA has accepted a Biologics License Application (BLA) seeking approval of nivolumab ...

The open-label, multicenter study included 157 patients enrolled in 2 cohorts: patients with carcinoma in situ (CIS) ± Ta/T1 (CIS cohort; n = 107) and patients with high-grade Ta/T1 without CIS ...